Live Breaking News & Updates on Acalabrutinib From

CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of promising early pipeline


New,. ....

United Kingdom , United States , San Diego Convention Center , San Diego , Anas Younes , Gianluca Pirozzi , Diego Marina , Liud Acalabrutinib , Hallb Manchester , National Study , Alexion Pharmaceuticals Inc , Patients Of The International , Astrazeneca Pharmaceuticals , Lymphoma Group , A Analysis Utilizing Electronic Health Records , Head Of Development , Outcomes Research , Hallsgh San Diego Convention Center , American Society Of Hematology , American Society , Annual Meeting , Rare Disease , Senior Vice President , Antibody Drug Conjugates , Treatment Naive Chronic Lymphocytic Leukemia , Lymphocytic Leukemia ,